Diagnosing Lower-Risk MDS
Experts review best practices for identifying and diagnosing patients with lower-risk MDS.
This is a video synopsis/summary of a Precision Medicine series featuring Hana Safah, MD, and Jamie Koprivnikar, MD. Safah and Koprivnikar discuss diagnosis and risk stratification of lower-risk myelodysplastic syndromes (MDS). Initial work-up rules out other causes of cytopenia before bone marrow biopsy to assess blasts and dysplasia. Cytogenetics, fluorescence in situ hybridization, and molecular mutation panels also are utilized, with increasing emphasis on mutations to enable precise classification.
Recently, the Mutation-Enhanced International Prognostic Scoring System (MIPSS) has helped patient stratification into risk groups beyond prior systems like the revised IPSS. By integrating genetic data, MIPSS allows more personalized prognosis and management decisions in MDS.
Ongoing advances in molecular characterization continue to shape diagnosis, prognostication, and treatment selection for this heterogeneous disease. The discussants note excitement regarding recent data at the 65th American Society of Hematology Annual Meeting and Exposition highlighting the promise of molecularly targeted approaches.
Video synopsis is AI generated and reviewed by Targeted Oncology™ editorial staff.
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
